IGFBP7 and persistent truncus arteriosus: Here we demonstrated antibody-mediated IGFBP7 neutralization in vivo through therapeutic delivery of IGFBP7 mAbs in a TAC mouse model; reversed IGFBP7 suppression of FOXO3a; restored anti-senescence pathways; and attenuated pressure-overload-induced HF in mice.